Cambria to elucidate molecular targets that have responded to Pfizer’s candidate parasiticidal compounds.
Cambria Biosciences www.cambriabio.com entered into a research collaboration agreement with Pfizer Animal Health www.pfizerah.com to guide the discovery and development of new classes of antiparasitic drug products.
Cambria Biosciences will use its chemical genetics platform to elucidate the molecular targets—and important functional sites within those targets—that have responded to Pfizer’s candidate parasiticidal compounds. The compounds have potentially novel modes of action that could overcome the resistance that parasites have developed to many current medicines.
Existing antiparasitic drugs act through a limited number of biochemical modes of action, all of which are threatened by increasing levels of drug resistance observed in the field. Thus, discovering and developing new antiparasitic drugs with novel modes of action is an industry-wide priority.
In helping Pfizer Animal Health identify the molecular targets of its novel candidate parasiticide products, Cambria’s genetic technologies offer numerous benefits. These include: strategies for identifying additional compounds with similar activity; accelerated market adoption through distinct product positioning; detailed safety profiles and benefit/risk ratios for regulatory agencies; and the potential for optimizing second-generation products for the novel molecular targets.
In addition, Cambria’s chemical genetic platform can create predictive models for the emergence and mode of compound resistance to aid in the field management and veterinary practice recommendations for an eventual product.
Under the terms of the present agreement, Pfizer Animal Health will provide milestone payments to Cambria for this program.